Uses of 6-aminohexanoic acid to manage bleeding conditions
AssigneeEmory University
InventorsHanna Jean Khoury, Ana Antun
Life of this patent
Estimating the term…
Abstract
This disclosure relates to the use of EACA (6-aminohexanoic acid) as an antifibrinolytic for the prevention of thrombocytopenic bleeds. In certain embodiment, the disclosure relates to methods of preventing bleeding in patients with thrombocytopenia resulting from hematological malignancies by administering 6-aminohexanoic acid, salts, or prodrugs thereof prophylactically to a subject in need thereof. In certain embodiments, subjects with stable chronic thrombocytopenia previously managed with platelet transfusion represent a selected group of patients that benefit from prophylaxis.
Claims11
A method of reducing the likelihood of spontaneous mucocutaneous bleeding consisting of administering twice daily a pharmaceutical composition comprising about 0.5 to 2.0 grams of 6-aminohexanoic acid or molar equivalent salt or prodrug thereof to a subject wherein the subject is absent bleeding and has a measured platelet count of less than 20×109/L, and wherein the administration is sustained for more than 30 days or until a measured platelet count is greater than 30 ×109/L.
Dependencies are inferred from the claim text.